Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
AVITA Medical, Inc. (RCEL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"AVITA Medical Reports Second Quarter Financial Results VALENCIA, California, August 10, 2023 — AVITA Medical, Inc. , a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today reported financial results for the second quarter June 30, 2023. Financial Highlights and Recent Updates • Commercial revenue of $11.7 million, a 42% increase compared to $8.2 million for the same period in 2022 • Received Food and Drug Administration approval of premarket approval supplement for the use of RECELL to treat full-thickness skin defects on June 7 • Initiated commercial launch of full-thickness skin defects, along with additional eligible burn procedures, with expanded U.S. comm..." |
|
| 06/15/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"AVITA Medical Announces Appointment of David O'Toole as Chief Financial Officer VALENCIA, Calif., June 15, 2023 and MELBOURNE, Australia, June 16, 2023 — AVITA Medical, Inc. , a regenerative medicine company leading the development and commercialization of first-in-class devices and autologous cellular therapies for skin restoration, today announced the appointment of David O'Toole as its new Chief Financial Officer, effective June 15, 2023. O'Toole is an accomplished financial executive with more than 30 years of experience in global corporate finance, capital markets, and accounting across biotech and life sciences companies. He has a demonstrated track record of developing and executing successful growth strategies in a number of public companies. O'Toole will play a critical role in ex..." |
|
| 06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 04/21/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
8-K
| Quarterly results |
| 03/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/21/2023 |
8-K
| Quarterly results |
| 03/08/2023 |
8-K
| Other Events Interactive Data |
| 03/02/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 02/10/2023 |
8-K
| Quarterly results |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
8-K
| Quarterly results |
| 09/30/2022 |
8-K
| Quarterly results |
| 09/22/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 09/13/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/02/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/30/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/12/2022 |
8-K
| Quarterly results |
| 07/22/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/29/2022 |
8-K
| Quarterly results |
| 04/21/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Avita Medical, Inc. Announces Resignation of Louis Drapeau from Board of Directors VALENCIA, Calif. 21 April 2022 and MELBOURNE, Australia, 22 April 2022 — AVITA Medical, Inc. , a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that Louis Drapeau has resigned, effective April 29, 2022, from the Company's Board of Directors. Mr. Drapeau's resignation is not because of a disagreement with the Company on any matter relating to the Company's operations, policies or practices. Rather, his resignation is due to personal reasons. Mr. Drapeau has been a non-executive Director of AVITA Medical since January 2016 and served as Chair of the Audit Committee. As di..." |
|
| 04/05/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/24/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AVITA Medical Announces Modification of BARDA Contract to Advance Development of RECELL ® System in Soft Tissue Reconstruction March 21, 2022 Funds will support completion of the ongoing pivotal clinical trial VALENCIA, Calif. and MELBOURNE, Australia, March 21, 2022 — AVITA Medical, Inc. , a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority has modified its existing contract with the Company to support AVITA Medical's clinical trial in soft tissue reconstruction. BARDA is a part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human...",
"Investor Webinar VALENCIA, Calif. and MELBOURNE, Australia, 22 March 2022 — AVITA Medical, Inc. , a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, invites shareholders and prospective investors to attend its investor webinar and presentation by Dr. Mike Perry, CEO, and Michael Holder, CFO, on Thursday at 11am 24 March 2022. The webinar will cover highlights from AVITA Medical's successful 2021 calendar year, multiple key accomplishments as previously announced over the past quarter and to date, and planned upcoming company milestones. Interested parties can register for the webinar using this link: https://zoom.us/webinar/register/WN_LgAAB_tyQGS6vyEPG1yAgw Participan...",
"RECELL ® System Vitiligo Clinical Trial Protocol to be Presented at the Global Vitiligo Foundation Annual Scientific Symposium VALENCIA, Calif. and MELBOURNE, Australia, 23 March 2022 — AVITA Medical, Inc. , a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that an abstract highlighting the clinical trial protocol utilizing the RECELL ® Autologous Cell Harvesting Device to treat vitiligo will be presented at the Global Vitiligo Foundation Annual Scientific Symposium. The conference is being held in Boston and will highlight research and knowledge of both up and coming vitiligo researchers and those who have and continue to build the foundational knowle..." |
|
| 03/09/2022 |
8-K
| Quarterly results |
| 03/04/2022 |
8-K
| Quarterly results |
| 03/01/2022 |
8-K
| Quarterly results |
| 02/24/2022 |
8-K
| Quarterly results |
| 02/18/2022 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 02/02/2022 |
8-K
| Quarterly results |
|
|
|